MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Prothena Corporation plc Total Non Current Liabilities 2011-2026 | PRTA
Annual Total Non Current Liabilities Prothena Corporation plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.7 M | 78.1 M | 85.8 M | 110 M | 123 M | 129 M | 161 M | 51.8 M | 53.5 M | 2.35 M | 2.19 M | 1.73 M | 1.06 M | 1.65 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | 1.06 M | 58 M |
Quarterly Total Non Current Liabilities Prothena Corporation plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.2 M | 6.93 M | 9.2 M | 11.7 M | 14.5 M | 16.9 M | 77.5 M | 78.1 M | 76.3 M | 67.4 M | 85.3 M | 85.8 M | 99.2 M | 102 M | 106 M | 110 M | 113 M | 95.3 M | 122 M | 123 M | 123 M | 123 M | 123 M | 129 M | 129 M | 129 M | 129 M | 161 M | 161 M | 161 M | 161 M | 51.8 M | 51.8 M | 51.8 M | 51.8 M | 53.5 M | 53.5 M | 53.5 M | 53.5 M | 2.35 M | 2.35 M | 2.35 M | 2.35 M | 2.19 M | 2.19 M | 2.19 M | 2.19 M | 1.73 M | 1.73 M | 1.73 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 161 M | 1.73 M | 67.6 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.56 | 2.13 % | $ 3.74 B | USA |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
Akebia Therapeutics
AKBA
|
168 M | $ 1.43 | 3.62 % | $ 368 M | USA |
 |
argenx SE
ARGX
|
226 M | $ 785.07 | 2.57 % | $ 25 B |  Niderland |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 327.25 | 2.42 % | $ 42.9 B | USA |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Aytu BioScience
AYTU
|
42.1 M | $ 2.66 | 3.5 % | $ 16.7 M | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.9 | 3.7 % | $ 9.38 B |  Australia |
 |
CymaBay Therapeutics
CBAY
|
1.26 M | - | - | $ 3.45 B | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 20.4 | -0.87 % | $ 954 M | USA |
 |
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.18 | 1.21 % | $ 447 M | USA |
 |
Avid Bioservices
CDMO
|
21.2 M | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
942 K | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 24.61 | 5.76 % | $ 3.13 B | USA |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 3.09 | 0.65 % | $ 310 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Concert Pharmaceuticals
CNCE
|
17.9 M | - | - | $ 401 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.49 | 9.56 % | $ 397 M | Britain |
 |
CTI BioPharma Corp.
CTIC
|
1.17 M | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
1.06 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
15.9 M | - | - | $ 2.18 B | USA |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
218 M | - | - | $ 2.02 B | USA |
|
Forte Biosciences
FBRX
|
10.5 M | $ 26.27 | 0.38 % | $ 340 M | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
50 K | $ 3.88 | 2.11 % | $ 261 B | Britain |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |